Vehicle-dependent Effects of Sphingosine 1-phosphate on Plasminogen Activator Inhibitor-1 Expression

  • Takahashi Chiharu
    Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo CREST, Japan Science and Technology Corporation (JST)
  • Kurano Makoto
    Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo CREST, Japan Science and Technology Corporation (JST)
  • Nishikawa Masako
    Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo CREST, Japan Science and Technology Corporation (JST)
  • Dohi Tomotaka
    Department of Cardiovascular Medicine, Juntendo University School of Medicine
  • Shimizu Tomo
    Tsukuba Research Institute, Research & Development Division, Sekisui Medical Co., Ltd.
  • Aoki Junken
    CREST, Japan Science and Technology Corporation (JST) Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University
  • Yatomi Yutaka
    Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo CREST, Japan Science and Technology Corporation (JST)
  • Kano Kuniyuki
    CREST, Japan Science and Technology Corporation (JST) Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University
  • Daida Hiroyuki
    Department of Cardiovascular Medicine, Juntendo University School of Medicine
  • Miyauchi Katsumi
    Department of Cardiovascular Medicine, Juntendo University School of Medicine

書誌事項

公開日
2017
資源種別
journal article
DOI
  • 10.5551/jat.37663
公開者
一般社団法人 日本動脈硬化学会

この論文をさがす

説明

<p>Aim: Sphingosine 1-phosphate (S1P) has been suggested to be a positive regulator of plasminogen activator inhibitor 1 (PAI-1) in adipocytes, while some studies are not consistent with this prothrombotic property of S1P. Since S1P is bound to apolipoprotein M (apoM) on HDL or to albumin in plasma, we compared the properties of these two forms on the PAI-1 induction.</p><p>Methods: We investigated the associations of S1P, apoM, and PAI-1 concentrations in the plasma of normal coronary artery (NCA), stable angina pectoris (SAP), and acute coronary syndrome (ACS) subjects (n=32, 71, and 38, respectively). Then, we compared the effects of S1P with various vehicles on the PAI-1 expression in 3T3L1 adipocytes. We also investigated the modulation of the PAI-1 levels in mice infected with adenovirus coding apoM.</p><p>Results: Among ACS subjects, the PAI-1 level was positively correlated with the S1P level, but not the apoM level. In adipocytes, S1P bound to an apoM-rich vehicle induced PAI-1 expression to a lesser extent than the control vehicle, while S1P bound to an apoM-depleted vehicle induced PAI-1 expression to a greater extent than the control vehicle in 3T3L1 adipocytes. Additionally, apoM overexpression in mice failed to modulate the plasma PAI-1 level and the adipose PAI-1 expression level. S1P bound to albumin increased PAI-1 expression through the S1P receptor 2-Rho/ROCK-NFκB pathway.</p><p>Conclusion: S1P bound to albumin, but not to apoM, induces PAI-1 expression in adipocytes, indicating that S1P can exert different properties on the pathogenesis of vascular diseases, depending on its vehicle.</p>

収録刊行物

被引用文献 (10)*注記

もっと見る

参考文献 (58)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ